The type 2 diabetes (T2D) drug market is expected to expand, fueled by a rich pipeline of agents. However, growth will be tempered because these emerging therapies will be predominantly later-to-market entrants of existing drug classes or combination treatments. Owing to the increased risk of cardiovascular (CV) and kidney disease associated with T2D, a high unmet need exists for affordable drugs that can safely and effectively manage this disease in the long term. The sodium-glucose co-transporter-2 (SGLT-2) inhibitors, such as AstraZeneca’s Farxiga / Forxiga, and glucagon-like peptide-1 (GLP-1) receptor agonists, such as Novo Nordisk’s Ozempic, are offering hope for greater CV and renal benefits. However, the physical and financial impacts of T2D continue to increase, highlighting the need for more-effective and more-affordable drug treatments.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals for type 2 diabetes?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for type 2 diabetes?
  • What are the prevailing areas of unmet need and opportunity in type 2 diabetes?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European endocrinologists for a hypothetical new type 2 diabetes drug?

PRODUCT DESCRIPTION

Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 32 European endocrinologists fielded in March 2020

Key companies: AstraZeneca, Eli Lilly, Janssen, Merck, Novo Nordisk

Key drugs: Farxiga / Forxiga, Invokana, Januvia, Jardiance, Rybelsus, Trulicity, Victoza

Table of contents

  • Detailed, Expanded Analysis (US/EU)
    • Executive Summary
      • Unmet Need - Type 2 Diabetes - Executive Summary - June 2020
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
      • Rationale for Drug Selection
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Key Findings: Stated vs. Derived Importance
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in Type 2 Diabetes
      • Key Findings: Unmet Need in Type 2 Diabetes and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Type 2 Diabetes Market and Emerging Therapy Insights
        • Opportunity: An Agent with Better Weight-Loss Efficacy
        • Opportunity: An Agent with Benefits in a Wider Range of Cardiovascular Diseases
        • Opportunity: an Agent Targeting Novel Pathways
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • Type 2 Diabetes Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulation of a Market Scenario
        • Market Scenario
    • Appendix
      • Bibliography

Author(s): Kerri Brown, M Pharm

Kerri Brown, is an analyst with Decision Resources Group, focused on finding stories in data and developing products to inform strategic decisions in the hemophilia and diabetes spaces. Kerri holds a master of pharmacy degree from King’s College London with 1 st class honors. Prior to joining DRG, she was a national clinical educator at a UK diabetes start-up, and has extensive experience of diabetes medical devices. Kerri has worked at AstraZeneca, and as a pharmacist in a national psychiatric clinical trial center. In addition to her work at DRG, Kerri is a practicing pharmacist with extensive clinical experience of UK physician prescribing in diabetes.


Related Reports

Type 2 Diabetes | Current Treatment | Detailed, Expanded Analysis: Physician Insights (US)

The highly genericized biguanides and sulfonylureas are, by far, the most heavily prescribed type 2 diabetes (T2D) drug classes. However, branded agents from...

View Details

Type 2 Diabetes | Landscape & Forecast | Disease Landscape & Forecast

The type 2 diabetes therapy market will steadily expand over the 2018-2028 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the d...

View Details

Type 2 Diabetes | Access & Reimbursement | Detailed, Expanded Analysis (US)

The treatment of type 2 diabetes places a significant economic burden on the U.S. healthcare system. Given the intense competition between antidiabetic therapies, the type 2 diabetes access and r...

View Details

Type 2 Diabetes | Geographic Focus: China | Type 2 Diabetes | China In-Depth | China

Type 2 diabetes (T2D) is one of the biggest health challenges in China, where the prevalence of disease is globally the highest. Traditional therapies such as...

View Details